Mirikizumab (Omvoh, Eli Lilly) is indicated for the treatment of 'adult patients with moderately to severely active Crohn's disease who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic treatment'.
The dosage schedule is available in the summary of product characteristics for mirikizumab.
The list price of the 300-mg concentrate solution for infusion used for induction treatment is £2,056.56 (excluding VAT, BNF online, accessed April 2025). The list price of 1 pre-filled pen of 200 mg plus 1 pre-filled pen of 100 mg for subcutaneous injection as maintenance treatment is £2,398.33 (excluding VAT, company communication).
The company has a commercial arrangement. This makes mirikizumab available to the NHS with a discount. The size of the discount is commercial in confidence.
For information, the Carbon Reduction Plan for UK carbon emissions is published on Eli Lilly's webpage on environmental sustainability.